SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Simple and cost-effective cancer diagnosis in liquid biopsy through native tRNA sequencing

This project aims to validate a cost-effective Nano-tRNAseq method for quantifying tRNA abundances and modifications as novel cancer biomarkers, facilitating early detection and potential commercialization.

Subsidie
€ 150.000
2025

Projectdetails

Introduction

Transfer RNAs (tRNAs) are abundant, heavily-modified small non-coding RNAs that play a pivotal role in decoding genetic information, determining which transcripts are highly and poorly translated at a given moment. Dysregulation of tRNA abundances and tRNA modifications is a well-known feature in cancer cells, leading to enhanced translation of specific oncogenic proteins.

Background

Despite the well-established association between tRNA dysregulation and cancer progression and malignancy, tRNA abundances and their modifications are still not being used as diagnostic or prognostic markers for cancer detection or progression. This is mainly due to the lack of a simple, unbiased, and cost-effective method to quantify tRNA abundances and their modifications.

Methodology

Our laboratory has recently established Nano-tRNAseq, a pioneering method that can accurately quantify both tRNA abundances and tRNA modifications using native tRNA nanopore sequencing, for a fraction of the cost of next-generation sequencing-based approaches.

Technical Approach

By employing a proprietary Nano-tRNAseq nanopore library preparation protocol coupled with deep learning algorithms that will rapidly classify the nanopore current signals, we aim to establish a method that exploits tRNAs as novel biomarkers through the use of third generation sequencing technologies.

Initial Findings

We have initial evidence of how our approach can separate cancer from non-cancer samples and possibly be used to identify the tissue of origin.

Project Goals

In this project, we will fully validate our technological platform for the differential analysis of low-input RNA amounts in liquid biopsy samples.

Future Applications

We will initially apply our method in the cancer arena, expandable to many other indications, following the advice of key stakeholders contacted so far. The goal is to lay the basis for the transfer of our technology to the marketplace, including through the creation of a new start-up company.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-1-2025
Einddatum30-6-2026
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • FUNDACIO CENTRE DE REGULACIO GENOMICApenvoerder

Land(en)

Spain

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Clone-based full-length RNA-seq for early diagnosis of cancer

Developing a novel 3D clone-based RNA-seq technology to enhance detection of rare mutations and splicing in cancer cells for improved early diagnosis and personalized treatment strategies.

ERC Proof of...€ 150.000
2022
Details

Detecting epigenetic biomarkers in the blood for non-invasive precision oncology

Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.

ERC Starting...€ 1.500.000
2022
Details

Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools

CO-TRANS-NET aims to create innovative synthetic nucleic acid units for simultaneous cancer diagnosis and therapy using cell-free transcription to enhance patient care.

ERC Starting...€ 1.499.750
2025
Details

Single-Clone Multi-omics Sequencing for Cancer Diagnosis

Developing MultiCloneSeq, a cost-effective single-cell multi-omics sequencing tool, to enhance cancer diagnosis by profiling genetic mutations and RNA expression simultaneously.

ERC Proof of...€ 150.000
2023
Details

Multiplexed microRNA detection platform for early diagnosis and patient management

The MiRACLE project aims to develop a cost-effective diagnostic platform for early disease detection by utilizing a novel optical sensing method to simultaneously detect individual micro-RNA molecules in bodily fluids.

ERC Proof of...€ 150.000
2024
Details
ERC Proof of...

Clone-based full-length RNA-seq for early diagnosis of cancer

Developing a novel 3D clone-based RNA-seq technology to enhance detection of rare mutations and splicing in cancer cells for improved early diagnosis and personalized treatment strategies.

ERC Proof of Concept
€ 150.000
2022
Details
ERC Starting...

Detecting epigenetic biomarkers in the blood for non-invasive precision oncology

Develop new non-invasive diagnostic methods for cancer by analyzing epigenetic markers in circulating tumor DNA to improve sensitivity and monitor disease evolution.

ERC Starting Grant
€ 1.500.000
2022
Details
ERC Starting...

Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools

CO-TRANS-NET aims to create innovative synthetic nucleic acid units for simultaneous cancer diagnosis and therapy using cell-free transcription to enhance patient care.

ERC Starting Grant
€ 1.499.750
2025
Details
ERC Proof of...

Single-Clone Multi-omics Sequencing for Cancer Diagnosis

Developing MultiCloneSeq, a cost-effective single-cell multi-omics sequencing tool, to enhance cancer diagnosis by profiling genetic mutations and RNA expression simultaneously.

ERC Proof of Concept
€ 150.000
2023
Details
ERC Proof of...

Multiplexed microRNA detection platform for early diagnosis and patient management

The MiRACLE project aims to develop a cost-effective diagnostic platform for early disease detection by utilizing a novel optical sensing method to simultaneously detect individual micro-RNA molecules in bodily fluids.

ERC Proof of Concept
€ 150.000
2024
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

VerSiLiB aims to develop an enzyme-free amplification platform for detecting proteins and nucleic acids in liquid biopsies, enhancing cancer management through novel affinity-mediated transport.

EIC Pathfinder€ 2.994.244
2022
Details

Best-in-class canceR dIaGnostic cHip for patient sTratification.

The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression.

EIC Accelerator€ 2.497.880
2022
Details

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.

EIC Transition€ 2.498.963
2023
Details

DETACT - Detection of Enzymes and muTAtions for Cancer Treatment

Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.

Mkb-innovati...€ 215.845
2019
Details
EIC Pathfinder

Versatile Amplification Method for Single-Molecule Detection in Liquid Biopsy

VerSiLiB aims to develop an enzyme-free amplification platform for detecting proteins and nucleic acids in liquid biopsies, enhancing cancer management through novel affinity-mediated transport.

EIC Pathfinder
€ 2.994.244
2022
Details
EIC Accelerator

Best-in-class canceR dIaGnostic cHip for patient sTratification.

The RUBYchip is a microfluidic liquid biopsy device that isolates and analyzes cancer cells from blood samples, enabling efficient and reliable monitoring of cancer progression.

EIC Accelerator
€ 2.497.880
2022
Details
EIC Transition

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery

TraffikGene-Tx aims to develop safe, scalable peptide carriers for targeted RNA delivery, addressing genetic diseases and enhancing NAT therapies to improve patient outcomes and reduce healthcare costs.

EIC Transition
€ 2.498.963
2023
Details
Mkb-innovati...

DETACT - Detection of Enzymes and muTAtions for Cancer Treatment

Cytura Therapeutics en ENPICOM ontwikkelen een innovatieve diagnostische assay voor vroege kankerdetectie door het meten van enzymactiviteit en mutatiepatronen in bloedcellen.

Mkb-innovatiestimulering Topsectoren R&D Samenwerking
€ 215.845
2019
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.